A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Saturday, 30 June 2012
Bristol-Myers Squibb and AstraZeneca expand diabetes alliance through Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion. The total value of the transaction, including Amylin’s net debt and a contractual payment obligation to Eli Lilly and Company, together totalling about $1.7 billion, is approximately $7 billion. The acquisition has been unanimously approved by the boards of directors of Bristol-Myers Squibb and Amylin. The board of directors of Amylin has unanimously recommended that Amylin’s stockholders tender their shares to the tender offer.
Monday, 25 June 2012
Seven Pharmaceutical Companies Join Academic Researchers to Speed TB Drug Discovery Groundbreaking partnership seeks rapid cure to reduce treatment time from six months to one month
Thursday, 21 June 2012
AstraZeneca completes acquisition of Ardea Biosciences AstraZeneca today announced that on Tuesday 19 June 2012 it completed its acquisition of San Diego, California-based biotechnology company Ardea Biosciences, Inc. The merger was approved by Ardea’s stockholders.
Tuesday, 19 June 2012
AstraZeneca and Rigel sign Worldwide license agreement for a potential new treatment for chronic Asthma AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel’s inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma.  In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.
Tuesday, 12 June 2012
Five additional pharmaceutical companies have joined a National Institutes of Health’s effort to help scientists research promising new treatments for patients. The programme is focused on discovering new therapeutic uses for existing molecules – a collaboration AstraZeneca already joined earlier this year.
Monday, 11 June 2012
AstraZeneca and Nobel Media bring Nobel Laureate Bruce Beutler to Boston On June 11-12, 2012, as part of a worldwide initiative between AstraZeneca, a global innovation-driven biopharmaceutical company, and Nobel Media AB, the company responsible for media rights for the Nobel Prize, students, researchers and staff at the Whitehead Institute for Biomedical Research and AstraZeneca’s Boston based Research and Development facility will have the opportunity to meet and learn from 2011 Nobel Laureate in Physiology or Medicine Dr Bruce Beutler.
Friday, 8 June 2012
Cancer Research UK launches trial of experimental drug combination for advanced stomach and oesophageal cancer Cancer Research UK’s Drug Development Office (DDO) has joined forces with academia and industry to open a clinical trial that will test an experimental drug from AstraZeneca called AZD4547 in combination with standard chemotherapy to treat a group of patients with advanced stomach or oesophageal cancer.
Thursday, 24 May 2012
Innovative public-private collaboration launches to tackle antibiotic research New €224m (£180m) funding to enable development of antibiotics for bacterial infections and drive unprecedented information sharing
Thursday, 3 May 2012
NIH launches collaborative program with industry and researchers Scientists will gain access to select compounds from Pfizer, AstraZeneca, and Lilly
Tuesday, 1 May 2012
Axerion Therapeutics and AstraZeneca to Develop and Commercialize a Biologic Approach for the Treatment of Alzheimer’s Disease Axerion Therapeutics, Inc., a private Connecticut-based biotechnology company, and MedImmune the global biologics arm of AstraZeneca, announced today that they have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's disease.